Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Dipersio, John F  [Clear All Filters]
Journal Article
Eissenberg LG, Rettig MP, Ritchey JK, Prior JL, Schwarz SW, Frye J, White BS, Fulton RS, Ghobadi A, Cooper ML, et al. [(18)F]FHBG PET/CT Imaging of CD34-TK75 Transduced Donor T cells in Relapsed Allogeneic Stem Cell Transplant Patients: Safety and Feasibility. Mol Ther. 2015.
Xie M, Lu C, Wang J, McLellan MD, Johnson KJ, Wendl MC, McMichael JF, Schmidt HK, Yellapantula V, Miller CA, et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med. 2014.
Rimando JC, Christopher MJ, Rettig MP, Dipersio JF. Biology of Disease Relapse in Myeloid Disease: Implication for Strategies to Prevent and Treat Disease Relapse After Stem-Cell Transplantation. J Clin Oncol. 2021:JCO2001587.
Ghobadi A, Foley NC, Cohen J, Rettig MP, Cashen AF, Gehrs LN, Christ S, Street E, Wallace N, Ritchey JK, et al. Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients with Diffuse Large B-Cell Lymphoma. Blood Adv. 2023.
Kansagra AJ, Frey NV, Bar M, Laetsch TW, Carpenter PA, Savani BN, Heslop HE, Bollard CM, Komanduri KV, Gastineau DA, et al. Clinical utilization of Chimeric Antigen Receptors T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL) - an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transpl. Biol Blood Marrow Transplant. 2018.
Huselton E, Rettig MP, Campbell K, Cashen AF, Dipersio JF, Gao F, Jacoby MA, Pusic I, Romee R, Schroeder MA, et al. Combination of dociparstat sodium (DSTAT), a CXCL12/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDS. Leuk Res. 2021;110:106713.
Crees ZD, Rettig MP, Bashey A, Devine SM, Jaglowski SM, Wan F, Zhou A, Harding M, Vainstein-Haras A, Sorani E, et al. Hematopoietic Stem Cell Mobilization for Allogeneic Stem Cell Transplantation by Motixafortide, a Novel CXCR4 Inhibitor. Blood Adv. 2023.
Christopher MJ, Petti AA, Rettig MP, Miller CA, Chendamarai E, Duncavage EJ, Klco JM, Helton NM, O'Laughlin M, Fronick CC, et al. Immune Escape of Relapsed AML Cells after Allogeneic Transplantation. N Engl J Med. 2018.
Xiang J, Shi M, Fiala MA, Gao F, Rettig MP, Uy GL, Schroeder MA, Weilbaecher KN, Stockerl-Goldstein K, Mollah S, et al. Machine learning-based scoring models to predict hematopoietic stem cell mobilization in allogeneic donors. Blood Adv. 2021.
Crees ZD, Rettig MP, Jayasinghe RG, Stockerl-Goldstein K, Larson SM, Arpad I, Milone GA, Martino M, Stiff P, Sborov D, et al. Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial. Nat Med. 2023.
Duncavage EJ, Jacoby MA, Chang GSu, Miller CA, Edwin N, Shao J, Elliott K, Robinson J, Abel H, Fulton RS, et al. Mutation Clearance after Transplantation for Myelodysplastic Syndrome. N Engl J Med. 2018;379(11):1028-1041.
Kim S, Ruminski P, Singh M, Staser K, Ashami K, Ritchey J, Lim S, Dipersio JF, Choi J. Novel JAK Inhibitors to Reduce Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation in a Preclinical Mouse Model. Molecules. 2024;29(8).
Rashidi A, Ebadi M, Colditz GA, Dipersio JF. Outcomes of allogeneic stem cell transplantation in elderly patients with acute myeloid leukemia: a systematic review and meta-analysis. Biol Blood Marrow Transplant. 2015.
Kramer MH, Zhang Q, Sprung R, Day RB, Erdmann-Gilmore P, Li Y, Xu Z, Helton NM, George DR, Mi Y, et al. Proteomic and Phosphoproteomic Landscapes of Acute Myeloid Leukemia. Blood. 2022.
Koreth J, Pidala J, Perez WS, H Deeg J, Garcia-Manero G, Malcovati L, Cazzola M, Park S, Itzykson R, Ades L, et al. Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative Decision Analysis. J Clin Oncol. 2013.
Ferraro F, Gao F, Stockerl-Goldstein K, Westervelt P, Dipersio JF, Ghobadi A. Secondary acute lymphoblastic leukemia, a retrospective analysis from Washington University and meta-analysis of published data. Leuk Res. 2018;72:86-91.
Alahmari B, Cooper M, Ziga E, Ritchey J, Dipersio JF, Choi J. Selective targeting of histone modification fails to prevent graft versus host disease after hematopoietic cell transplantation. PLoS One. 2018;13(11):e0207609.
Cancilla D, Rettig MP, Karpova D, Thakellapalli H, Singh M, Meyers MJ, Ruminski PG, Christ S, Chendamarai E, Gao F, et al. Targeting CXCR4, VLA-4 and CXCR2 for Hematopoietic Stem Cell Mobilization. Blood Adv. 2024.